-
FDA Grants Approval to DUVYZAT™ (Givinostat)
PPMD is excited to learn that the FDA has granted approval to DUVYZAT (givinostat), a […]
-
Duchenne clinical trials show me how mature my sons have become
I recently took my three sons with Duchenne muscular dystrophy (DMD) to a hospital in […]
-
FDA approves oral givinostat, as Duvyzat, to treat Duchenne MD
The U.S. Food and Drug Administration (FDA) has approved Italfarmaco’s givinostat, which will now be […]
-
ITF Therapeutics Shares Update on DUVYZAT™ Following FDA Approval
Following the FDA’s approval of DUVYZAT (givinostat) on March 21, 2024, ITF Therapeutics, LLC, the […]
-
These College Scholarships are Open to People with Disabilities
Going to college can be a life changing experience – from meeting new friends to […]
-
PPMD’s 2024 Advocacy Conference Brings Together Community to Support Progress in Fighting for Every Future
Earlier this month, more than 120 PPMD advocates – people with Duchenne and Becker, parents, […]
-
WATCH: Sarepta Therapeutics – Data update from MOMENTUM study, SRP-5051 (Webinar Recording)
Sarepta Therapeutics recently joined PPMD for a community webinar: Data Update From the MOMENTUM Study […]
-
PTC Therapeutics Announces Plans to Resubmit Translarna™ NDA to FDA
PTC Therapeutics, Inc. has announced that based on recent feedback from the FDA, the company […]
-
Agamree, next-gen steroid, now available for DMD patients in US
Agamree (vamorolone) is now available for Duchenne muscular dystrophy (DMD) patients, ages 2 and older, […]
-
PTC Therapeutics Provides Key Regulatory Updates
PTC Therapeutics announced that, based on recent feedback from the FDA, by mid-year they plan […]
